Surveillance of the in vitro activity of eravacycline and comparators against clinical isolates from the US from 2016

Author(s):
Sam Bouchillon; Stephen Hawser; Federica Monti; Ian Morrissey; Melanie Olesky; Kenneth Lawrence; Corey Fyfe

Background:

Eravacycline is a novel, fully-synthetic, fluorocycline antibiotic that has completed phase 3 clinical development for the treatment of complicated intra-abdominal infections and is in phase 3 clinical development for patients with complicated urinary tract infection.  We report the in vitro activity of eravacycline and comparators against clinical isolates from patients in the United States isolated during 2014-2016.

Hypothesis:

None

Methods:

A total of 7,815 non-duplicate, non-consecutive, single-patient clinical isolates were collected during 2014- 2016 from hospitals throughout the United States. These comprised Enterobacteriaceae (n = 5142), Acinetobacter baumannii (n = 717) and 1,956 Gram-positive isolates. Isolates were from multiple infection sources including blood, body fluids, gastrointestinal, genitourinary, skin, respiratory amongst others. MICs were determined by CLSI broth microdilution.  Antibiotic susceptibility was interpreted using CLSI breakpoints, where available.  FDA breakpoints were used for tigecycline.

Results:

Summary MIC data for eravacycline and tigecycline are shown in the Table. Eravacycline exhibited potent activity and was 2 to 4-fold more active than tigecycline against the majority of both Gram-negative and Gram-positive clinical isolates.  Tigecycline resistance ranged from 0 to 16.6%.

Conclusions:

Overall, eravacycline exhibited potent in vitro activity against these clinically-important isolates and was several fold more active than tigecycline.